Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
SNSE
Sensei Biotherapeutics, Inc.
Sensei's lead asset targets oncology/cancer indications, fitting the Biotech - Oncology category.
|
$10.66M |
$8.75
+1.74%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$10.59M |
$1.37
+1.48%
|
|
COCP
Cocrystal Pharma, Inc.
Cocrystal Pharma is actively developing antiviral small-molecule therapeutics (CC-42344, CDI-988, CC-31244) for influenza, norovirus/coronavirus, and HCV.
|
$10.36M |
$1.02
+8.31%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$10.31M |
$0.82
-0.35%
|
|
MRAI
Marpai, Inc.
PBMs (Pharmacy Benefit Managers) theme reflecting MarpaiRx's prescription cost management objectives.
|
$10.30M |
$0.90
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$10.14M |
$0.40
+6.35%
|
|
MDXH
MDxHealth S.A.
MDxHealth's portfolio includes liquid-based diagnostic tests (Select mdx, Resolve mdx, ExoDx) that fit the Liquid Biopsy category.
|
$10.01M |
$3.65
+1.96%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$10.00M |
$1.05
-3.21%
|
|
QURT
Quarta-Rad, Inc.
Geiger counters and radiation-detection devices are diagnostic/instrumentation equipment, mapping to Diagnostic Equipment.
|
$9.99M |
$0.72
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$9.98M |
$1.02
+0.99%
|
|
IMRN
Immuron Limited
Core polyclonal antibody technology platform powering gut-health products and clinical programs in immunology/biotherapeutics.
|
$9.97M |
$1.76
+1.44%
|
|
TNON
Tenon Medical, Inc.
Catamaran SI Joint Fusion System and related SI implants are orthopedic devices sold as implants for sacroiliac fusion.
|
$9.94M |
$1.13
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$9.83M |
$0.65
+7.77%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$9.83M |
$2.17
+3.10%
|
|
LUDG
Ludwig Enterprises, Inc.
Development of non-invasive diagnostic tests/biomarker-based technology qualifies as medical devices & biometrics.
|
$9.75M |
$0.05
|
|
VASO
Vaso Corporation
Vaso develops and sells medical devices and biometrics-related technology (cardiovascular focus).
|
$9.74M |
$0.14
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$9.58M |
$0.38
+0.18%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$9.55M |
$0.59
-1.05%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt is a clinical-stage biotech focused on oncology immunotherapies, making 'Biotech - Oncology' a core investable theme.
|
$9.50M |
$5.08
+0.30%
|
|
CHEK
Check-Cap Ltd.
Check-Cap historically manufactured medical devices and biometric sensing technologies, including C-Scan components.
|
$9.42M |
$1.63
+3.16%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$9.12M |
$2.04
+7.94%
|
|
LFWD
Lifeward Ltd.
LFWD directly designs, manufactures, and sells medical devices (exoskeletons, anti-gravity systems, and rehabilitation solutions), fitting Medical Devices & Biometrics.
|
$9.01M |
$0.57
-1.39%
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$9.00M |
$1.46
+11.07%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$8.98M |
$1.25
+6.36%
|
|
EPIX
ESSA Pharma Inc.
Directly describes a biotech company focused on oncology drug development (masofaniten) with no revenue; core business is cancer therapeutics.
|
$8.93M |
$0.20
|
|
VSEE
VSee Health, Inc.
Healthcare Services & Facilities; telehealth services delivered to healthcare providers.
|
$8.87M |
$0.53
-11.72%
|
|
APYP
AppYea, Inc.
AppySleep devices function as medical devices/biometrics for sleep disorders.
|
$8.80M |
$0.02
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$8.78M |
$1.11
|
|
PTHL
Pheton Holdings Ltd Class A Ordinary Shares
The company operates a software-driven planning/diagnostic workflow used in radiology/medical imaging, which can be associated with the diagnostic equipment category.
|
$8.70M |
$0.60
+4.64%
|
|
ICU
SeaStar Medical Holding Corporation
Core product is a blood purification device (SCD) used in critical care to modulate immune response and remove inflammatory mediators, fitting Blood Purification Devices.
|
$8.50M |
$0.30
-5.00%
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$8.48M |
$0.28
-23.39%
|
|
BNGO
Bionano Genomics, Inc.
BNGO directly manufactures and sells diagnostic instrument hardware used for Optical Genome Mapping (OGM).
|
$8.47M |
$1.81
+4.31%
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$8.46M |
$3.94
+3.68%
|
|
HCWC
Healthy Choice Wellness Corp.
HCWC runs licensed wellness centers offering services such as IV nutrient drips, i.e., Healthcare Services & Facilities.
|
$8.38M |
$0.62
+0.02%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$8.30M |
$1.43
-0.35%
|
|
BLRX
BioLineRx Ltd.
Motixafortide's use in gene therapy mobilization aligns the company with gene therapy-focused themes.
|
$8.26M |
$3.44
-3.10%
|
Showing page 34 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
